Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
Titel:
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
Auteur:
Sands, Bruce E. Chen, Jingjing Feagan, Brian G. Penney, Mark Rees, William A. Danese, Silvio Higgins, Peter D.R. Newbold, Paul Faggioni, Raffaella Patra, Kaushik Li, Jing Klekotka, Paul Morehouse, Chris Pulkstenis, Erik Drappa, Jörn van der Merwe, René Gasser Jr., Robert A.